Reported Saturday, Syndax's Revuforj (Revumenib) Achieves High Response Rates In Acute Leukemia Trials, Presents Compelling Data At ASH 2024
Reported Saturday, Syndax's Revuforj (Revumenib) Achieves High Response Rates In Acute Leukemia Trials, Presents Compelling Data At ASH 2024
據報道，Syndax的Revuforj（Revumenib）在急性白血病試驗中取得了高響應率，並在2024年ASH大會上展示了引人注目的數據。
- 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML –
- 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to proceed to HSCT in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –
- Responses were rapid, durable and observed across all major subgroups in expanded dataset of Ph 2 R/R KMT2Ar acute leukemia patients in AUGMENT-101 –
- Latest data highlight the compelling clinical profile of revumenib and support advancement into combination trials in the frontline setting –
- SAVE試驗研究中，revumenib與venetoclax和decitabine/cedazuridine聯合應用，在R/R AML中達到82%的ORR（33份中的27份）和48%的CR/CRh（33份中的16份）
- AUGMENt-101中擴展數據集顯示，KMT2Ar急性白血病R/R患者中，64%的ORR（97份中的62份）和23%的CR/CRh（97份中的22份），MRD陰性率高，可以進行HSCt，數據顯示在所有主要亞組中觀察到快速、持久的反應
- AUGMENt-101中擴展數據集中的R/R KMT2Ar急性白血病患者，反應迅速、持久，且在所有主要亞組中都有觀察到
- 最新數據突出revumenib引人注目的臨床概況，並支持進入前線組合試驗
資訊熱榜
更新時間